Hjem
Universitetet i Bergen
Magdhy El-Salhys bilde

Magdhy El-Salhy

Gjesteforsker
Klinisk institutt 1
  • E-postmagdy.el-salhy@uib.no
  • Besøksadresse
    Haukeland Universitetssykehus Laboratoriebygget, 7. etg. Heis øst
    5009 Bergen
  • Postadresse
    Postboks 7804
    5020 Bergen
Vitenskapelig artikkel
  • Vis forfatter(e) (2024). Factors Underlying the Difference in Response to Fecal Microbiota Transplantation Between IBS Patients with Severe and Moderate Symptoms. Digestive Diseases and Sciences.
  • Vis forfatter(e) (2023). Increasing the transplant dose and repeating faecal microbiota transplantation results in the responses of male patients with IBS reaching those of females. Scandinavian Journal of Gastroenterology.
  • Vis forfatter(e) (2023). Factors affecting the outcome of fecal microbiota transplantation for patients with irritable bowel syndrome. Neurogastroenterology and Motility.
  • Vis forfatter(e) (2022). The fecal microbiota transplantation response differs between patients with severe and moderate irritable bowel symptoms. Scandinavian Journal of Gastroenterology. 1036-1045.
  • Vis forfatter(e) (2022). Irritable bowel syndrome patients who are not likely to respond to fecal microbiota transplantation. Neurogastroenterology and Motility. 1-7.
  • Vis forfatter(e) (2022). Efficacy of fecal microbiota transplantation for patients with irritable bowel syndrome at 3 years after transplantation. Gastroenterology. 1-27.
  • Vis forfatter(e) (2022). Changes in colonic enteroendocrine cells of patients with irritable bowel syndrome following fecal microbiota transplantation. Scandinavian Journal of Gastroenterology. 792-796.
  • Vis forfatter(e) (2021). The Effects of Fecal Microbiota Transplantation on the Symptoms and the Duodenal Neurogenin 3, Musashi 1, and Enteroendocrine Cells in Patients With Diarrhea-Predominant Irritable Bowel Syndrome. Frontiers in Cellular and Infection Microbiology. 1-12.
  • Vis forfatter(e) (2021). Responses to faecal microbiota transplantation in female and male patients with irritable bowel syndrome. World Journal of Gastroenterology (WJG). 2219-2237.
  • Vis forfatter(e) (2021). Long-term effects of fecal microbiota transplantation (FMT) in patients with irritable bowel syndrome. Neurogastroenterology and Motility.
  • Vis forfatter(e) (2020). Density of Musashi‑1‑positive stem cells in the stomach of patients with irritable bowel syndrome. Molecular Medicine Reports. 3135-3140.
  • Vis forfatter(e) (2020). Changes in fecal short-chain fatty acids following fecal microbiota transplantation in patients with irritable bowel syndrome. Neurogastroenterology and Motility.
  • Vis forfatter(e) (2019). Overlapping of irritable bowel syndrome with erosive esophagitis and the performance of Rome criteria in diagnosing IBS in a clinical setting. Molecular Medicine Reports. 787-794.
  • Vis forfatter(e) (2019). Increasing the Dose and/or Repeating Faecal Microbiota Transplantation (FMT) Increases the Response in Patients with Irritable Bowel Syndrome (IBS). Nutrients.
  • Vis forfatter(e) (2019). Efficacy of faecal microbiota transplantation for patients with irritable bowel syndrome in a randomised, double-blind, placebo-controlled study . Gut. 1-9.
  • Vis forfatter(e) (2019). Efficacy of faecal microbiota transplantation for patients with irritable bowel syndrome in a randomised, double-blind, placebo-controlled study. Gut.
  • Vis forfatter(e) (2019). Diet in Irritable Bowel Syndrome (IBS): Interaction with Gut Microbiota and Gut Hormones. Nutrients. 1-15.
  • Vis forfatter(e) (2019). Clinical response to fecal microbiota transplantation in patients with diarrhea-predominant irritable bowel syndrome is associated with normalization of fecal microbiota composition and short-chain fatty acid levels. Scandinavian Journal of Gastroenterology. 690-699.
  • Vis forfatter(e) (2018). The kinetics of gut microbial community composition in patients with irritable bowel syndrome following fecal microbiota transplantation. PLOS ONE. 1-17.
  • Vis forfatter(e) (2017). Interaction between diet and gastrointestinal endocrine cells. Biomedical Reports. 651-656.
  • Vis forfatter(e) (2017). Enteroendocrine, Musashi 1 and neurogenin 3 cells in the large intestine of Thai and Norwegian patients with irritable bowel syndrome. Scandinavian Journal of Gastroenterology. 1331-1339.
  • Vis forfatter(e) (2017). Chromogranin A cell density in the large intestine of Asian and European patients with irritable bowel syndrome. Scandinavian Journal of Gastroenterology. 691-697.
  • Vis forfatter(e) (2017). Changes in duodenal enteroendocrine cells in patients with irritable bowel syndrome following dietary guidance. Experimental biology and medicine. 1355-1362.
  • Vis forfatter(e) (2017). Abnormalities in ileal stem, neurogenin 3, and enteroendocrine cells in patients with irritable bowel syndrome. BMC Gastroenterology. 1-9.
  • Vis forfatter(e) (2017). Abnormal differentiation of stem cells into enteroendocrine cells in rats with DSS-induced colitis. Molecular Medicine Reports. 2106-2112.
  • Vis forfatter(e) (2016). Treatment with novel AP-1 and NF-B inhibitors restores the colonic endocrine cells to normal levels in rats with DSS-induced colitis. International Journal of Molecular Medicine. 556-564.
  • Vis forfatter(e) (2016). The role of the neuropeptide Y (NPY) family in the pathophysiology of inflammatory bowel disease (IBD). Neuropeptides. 137-144.
  • Vis forfatter(e) (2016). Enteroendocrine cells, stem cells and differentiation progenitors in rats with TNBS-induced colitis. International Journal of Molecular Medicine. 1743-1751.
  • Vis forfatter(e) (2016). Effects of AP-1 and NF-κB inhibitors on colonic endocrine cells in rats with TNBS-induced colitis. Molecular Medicine Reports. 1515-1522.
  • Vis forfatter(e) (2016). Dietary guidance normalizes large intestinal endocrine cell densities in patients with irritable bowel syndrome. European Journal of Clinical Nutrition. 175-181.
  • Vis forfatter(e) (2016). Dietary guidance and ileal enteroendocrine cells in patients with irritable bowel syndrome. Experimental and Therapeutic Medicine. 1398-1404.
  • Vis forfatter(e) (2016). Changes in small intestinal chromogranin A-immunoreactive cell densities in patients with irritable bowel syndrome after receiving dietary guidance. International Journal of Molecular Medicine. 1247-1253.
  • Vis forfatter(e) (2016). Changes in enteroendocrine and immune cells following colitis induction by TNBS in rats. Molecular Medicine Reports. 4967-4974.
  • Vis forfatter(e) (2016). Anti-inflammatory effects of novel AP-1 and NF-B inhibitors in dextran-sulfate-sodium-induced colitis in rats. International Journal of Molecular Medicine. 1457-1464.
  • Vis forfatter(e) (2016). Abnormalities in endocrine and immune cells are correlated in dextran‑sulfate‑sodium‑induced colitis in rats. Molecular Medicine Reports. 12-20.
  • Vis forfatter(e) (2015). Reduction in duodenal endocrine cells in irritable bowel syndrome is associated with stem cell abnormalities. World Journal of Gastroenterology (WJG). 9577-9587.
  • Vis forfatter(e) (2015). Recent developments in the pathophysiology of irritable bowel syndrome. World Journal of Gastroenterology (WJG). 7621-7636.
  • Vis forfatter(e) (2015). Increased chromogranin A cell density in the large intestine of patients with irritable bowel syndrome after receiving dietary guidance. Gastroenterology Research and Practice. 8 sider.
  • Vis forfatter(e) (2015). Effect of dietary management on the gastric endocrine cells in patients with irritable bowel syndrome. European Journal of Clinical Nutrition. 519-524.
  • Vis forfatter(e) (2015). Diet in irritable bowel syndrome. Nutrition Journal.
  • Vis forfatter(e) (2015). Densities of rectal peptide YY and somatostatin cells as biomarkers for the diagnosis of irritable bowel syndrome. Peptides. 12-19.
  • Vis forfatter(e) (2014). Stomach antral endocrine cells in patients with irritable bowel syndrome. International Journal of Molecular Medicine. 967-974.
  • Vis forfatter(e) (2014). Increased gastric chromogranin A cell density following changes to diets of patients with irritable bowel syndrome. Molecular Medicine Reports. 2322-2326.
  • Vis forfatter(e) (2014). Endocrine cells in the oxyntic mucosa of the stomach in patients with irritable bowel syndrome. World Journal of Gastrointestinal Endoscopy (WJGE). 176-185.
  • Vis forfatter(e) (2014). Endocrine cells in the ileum of patients with irritable bowel syndrome. World Journal of Gastroenterology (WJG). 2383-2391.
  • Vis forfatter(e) (2014). Duodenal Chromogranin A Cell Density as a Biomarker for the Diagnosis of Irritable Bowel Syndrome. Gastroenterology Research and Practice. 8 sider.
  • Vis forfatter(e) (2014). Chromogranin A cells in the stomachs of patients With sporadic irritable bowel syndrome. Molecular Medicine Reports. 1753-1757.
  • Vis forfatter(e) (2014). Amelioration of Severe TNBS Induced Colitis by Novel AP-1 and NF-κB Inhibitors in Rats. Scientific World Journal. 8 sider.
  • Vis forfatter(e) (2014). Abnormal rectal endocrine cells in patients with irritable bowel syndrome. Regulatory Peptides. 60-65.
  • Vis forfatter(e) (2013). Serotonin and serotonin transporter in the rectum of patients with irritable bowel disease. Molecular Medicine Reports. 451-455.
  • Vis forfatter(e) (2013). Reduced chromogranin A cell density in the ileum of patients with irritable bowel syndrome. Molecular Medicine Reports. 1241-1244.
  • Vis forfatter(e) (2013). Low‑grade inflammation in the rectum of patients with sporadic irritable bowel syndrome. Molecular Medicine Reports. 1081-1085.
  • Vis forfatter(e) (2013). Increased serotonin transporter immunoreactivity intensity in the ileum of patients with irritable bowel disease. Molecular Medicine Reports. 180-184.
  • Vis forfatter(e) (2013). Evaluation of the usefulness of colonoscopy with mucosal biopsies in the follow-up of TNBS-induced colitis in rats. Molecular Medicine Reports. 446-450.
  • Vis forfatter(e) (2013). Effects of dietary guidance on the symptoms, quality of life and habitual dietary intake of patients with irritable bowel syndrome. Molecular Medicine Reports. 845-852.
  • Vis forfatter(e) (2013). Colonoscopy with mucosal biopsies in young rats: A model for experimental gastroenterology. Molecular Medicine Reports. 1757-1760.
  • Vis forfatter(e) (2013). Changes in the symptom pattern and the densities of large-intestinal endocrine cells following Campylobacter infection in irritable bowel syndrome: a case report. BMC Research Notes. 11 sider.
  • Vis forfatter(e) (2012). The role of diet in the pathogenesis and management of irritable bowel syndrome (Review). International Journal of Molecular Medicine. 723-731.
  • Vis forfatter(e) (2012). Low Densities of Serotonin and Peptide YY Cells in the Colon of Patients with Irritable Bowel Syndrome. Digestive Diseases and Sciences. 873-878.
  • Vis forfatter(e) (2012). Irritable bowel syndrome: the role of gut neuroendocrine peptides. Frontiers in Bioscience-Elite (FBE). 2783-2800.
  • Vis forfatter(e) (2012). Irritable bowel syndrome: Diagnosis and pathogenesis. World Journal of Gastroenterology (WJG). 5151-5163.
  • Vis forfatter(e) (2012). High densities of serotonin and peptide YY cells in the colon of patients with lymphocytic colitis. World Journal of Gastroenterology (WJG). 6070-6075.
  • Vis forfatter(e) (2012). Diet and effects of diet management on quality of life and symptoms in patients with irritable bowel syndrome. Molecular Medicine Reports. 1382-1390.
  • Vis forfatter(e) (2012). Chromogranin A cell density in the rectum of patients with irritable bowel syndrome. Molecular Medicine Reports. 1223-1225.
  • Vis forfatter(e) (2012). Chromogranin A cell density as a diagnostic marker for lymphocytic colitis. Digestive Diseases and Sciences. 3154-3159.
  • Vis forfatter(e) (2011). The prevalence of inflammatory bowel diseases, microscopic colitis, and colorectal cancer in patients with irritable bowel syndrome. Gastroenterology Insights. 7-10.
  • Vis forfatter(e) (2011). The prevalence of celiac disease in patients with irritable bowel syndrome. Molecular Medicine Reports. 403-405.
  • Vis forfatter(e) (2011). High chromogranin A cell density in the colon of patients with lymphocytic colitis. Molecular Medicine Reports. 603-605.
  • Vis forfatter(e) (2010). Relative importance of abnormalities of CCK and 5-HT (serotonin) in Giardia-induced post-infectious irritable bowel syndrome and functional dyspepsia. Alimentary Pharmacology and Therapeutics. 883-891.
  • Vis forfatter(e) (2010). Effects of a health program comprising reassurance, diet management, probiotics administration and regular exercise on symptoms and quality of life in patients with irritable bowel syndrome. Gastroenterology Insights. 21-26.
  • Vis forfatter(e) (2010). Chromogranin A as a possible tool in the diagnosis of irritable bowel syndrome. Scandinavian Journal of Gastroenterology. 1435-1439.
  • Vis forfatter(e) (2010). Abnormal small-intestinal endocrine cells in patients with irritable bowel syndrome. Digestive Diseases and Sciences. 3508-3513.
  • Vis forfatter(e) (2009). Low density of ghrelin cells in the oxyntic mucosa correlated to slow gastric emptying in patients with type 1 diabetes. Molecular Medicine Reports. 893-896.
  • Vis forfatter(e) (2009). Ghrelin in patients with irritable bowel syndrome. International Journal of Molecular Medicine. 703-707.
  • Vis forfatter(e) (2009). Ghrelin in gastrointestinal diseases and disorders: A possible role in the pathophysiology and clinical implications (Review). International Journal of Molecular Medicine. 727-732.
Faglig foredrag
  • Vis forfatter(e) (2016). Kinetics of microbial community composition in patients with diarrhea-predominant irritable bowel syndrome following faecal microbiota transplantation.
Vitenskapelig foredrag
  • Vis forfatter(e) (2023). Epidemiologi og patofysiologi ved diabetisk diaré (DIAREPA).
  • Vis forfatter(e) (2020). Long-term effects of faecal microbiota transplantation (FMT) in patients with irritable bowel syndrome.
  • Vis forfatter(e) (2019). Effect of faecal microbiota transplantation on gut microenvironment and symptoms in patients with irritable bowel syndrome.
Leder
  • Vis forfatter(e) (2019). Nutritional management of gastrointestinal diseases and disorders. Nutrients.
  • Vis forfatter(e) (2016). Diet in the pathophysiology and management of irritable bowel syndrome. Cleveland Clinic journal of medicine. 663-664.
Vitenskapelig monografi
  • Vis forfatter(e) (2015). Understanding and Controlling the Irritable Bowel.
Fagbok
  • Vis forfatter(e) (2012). Irritable Bowel Syndrome: Diagnosis, Pathogenesis and Treatment Options. Nova Science Publishers.
Brev til redaktøren
  • Vis forfatter(e) (2023). Letter: A step forward towards a standard FMT protocol for IBS. Alimentary Pharmacology and Therapeutics. 1115-1116.
  • Vis forfatter(e) (2021). FMT in IBS: How cautious should we be? Gut. 626-628.
  • Vis forfatter(e) (2020). Letter: faecal microbiota transplantation for irritable bowel syndrome—which improvements are required? Alimentary Pharmacology and Therapeutics. 1752-1753.
Doktorgradsavhandling
  • Vis forfatter(e) (2015). The Role of Diet in Irritable Bowel Syndrome with special reference to Gut Neuroendocrine System.
Intervju
  • Vis forfatter(e) (2016). Irritabel tarm – fra psykisk til fysisk.
Vitenskapelig Kapittel/Artikkel/Konferanseartikkel
  • Vis forfatter(e) (2013). Diet and Irritable Bowel Syndrome, with a Focus on Appetite-Regulating Gut Hormones. 13 sider.
Sammendrag/abstract
  • Vis forfatter(e) (2021). Responses to faecal microbiota transplantation in female and male patients with irritable bowel syndrome. United European Gastroenterology Journal (UEG Journal). 635-636.
  • Vis forfatter(e) (2020). Long-term effects of faecal microbiota transplantation (FMT) in patients with irritable bowel syndrome. United European Gastroenterology Journal (UEG Journal). 46-46.
  • Vis forfatter(e) (2020). Changes in fecal short-chain fatty acids (SCFA) following fecal microbiota transplantation (FMT) in patients with irritable bowel syndrome (IBS). Neurogastroenterology and Motility.
  • Vis forfatter(e) (2018). Effects of faecal microbiota transplantation on gut microenvironment and symptoms in patients with irritable bowel syndrome. Neurogastroenterology and Motility. 178-179.
  • Vis forfatter(e) (2017). Effect of faecal microbiota transplantation on the symptoms and gut microbiota in patients with irritable bowel syndrome (IBS). Neurogastroenterology and Motility. 73-74.
  • Vis forfatter(e) (2017). Effect of faecal microbiota transplantation on gut bacterial fermentation products in patients with irritable bowel syndrome. United European Gastroenterology Journal (UEG Journal). A563-A564.
  • Vis forfatter(e) (2017). Effect of faecal microbiota transplantation on Neurogenin 3, Musahsi 1 and enteroendocrine cells in the duodenum of patients with irritable bowel syndrome. United European Gastroenterology Journal (UEG Journal). 785-786.
  • Vis forfatter(e) (2016). Kinetics of microbial community composition in patients with diarrhea-predominant irritable bowel syndrome following faecal microbiota transplantation. United European Gastroenterology Journal (UEG Journal). LB11-LB11.
  • Vis forfatter(e) (2016). Effect of fecal microbiota transplantation on the symptoms and duodenal enteroendocrine cells in patients with irritable bowel syndrome. United European Gastroenterology Journal (UEG Journal). 677-677.
  • Vis forfatter(e) (2011). Low densities of serotonin and peptide YY cells in the colon of patients with irritable bowel syndrome. International Journal of Molecular Medicine. S10-S10.
  • Vis forfatter(e) (2009). Low density of ghrelin cells in the oxyntic mucosa correlated to slow gastric emptying in patients with diabetes type 1. International Journal of Molecular Medicine. S73-S73.
Poster
  • Vis forfatter(e) (2021). Responses to faecal microbiota transplantation in female and male patients with irritable bowel syndrome.
  • Vis forfatter(e) (2018). Effects of faecal microbiota transplantation on gut microenvironment and symptoms in patients with irritable bowel syndrome.
  • Vis forfatter(e) (2017). Effect of faecal microbiota transplantation on gut bacterial fermentation products in patients with irritable bowel syndrome.
  • Vis forfatter(e) (2017). Effect of faecal microbiota transplantation on Neurogenin 3, Musahsi 1 and enteroendocrine cells in the duodenum of patients with irritable bowel syndrome.
Vitenskapelig oversiktsartikkel/review
  • Vis forfatter(e) (2023). Intestinal bacteria associated with irritable bowel syndrome and chronic fatigue. Neurogastroenterology and Motility.
  • Vis forfatter(e) (2021). The role of diet in the pathophysiology and management of irritable bowel syndrome. Indian Journal of Gastroenterology. 1-9.
  • Vis forfatter(e) (2021). Inhibition of cellular and animal inflammatory disease models by nf-κb inhibitor dhmeq. Cells.
  • Vis forfatter(e) (2021). Current status of fecal microbiota transplantation for irritable bowel syndrome. Neurogastroenterology and Motility. 1-8.
  • Vis forfatter(e) (2020). Possible role of intestinal stem cells in the pathophysiology of irritable bowel syndrome. World Journal of Gastroenterology (WJG). 1427-1438.
  • Vis forfatter(e) (2019). Possible role of peptide YY (PYY) in the pathophysiology of irritable bowel syndrome (IBS). Nutrients. 1-7.
  • Vis forfatter(e) (2018). Fecal microbiota transplantation for managing irritable bowel syndrome. Expert Review of Gastroenterology & Hepatology. 439-445.
  • Vis forfatter(e) (2017). Gastrointestinal neuroendocrine peptides/amines in inflammatory bowel Disease. World Journal of Gastroenterology (WJG). 5068-5085.
  • Vis forfatter(e) (2017). Effect of diet and individual dietary guidance on gastrointestinal endocrine cells in patients with irritable bowel syndrome (Review). International Journal of Molecular Medicine. 943-952.
  • Vis forfatter(e) (2017). Dietary fiber in irritable bowel syndrome (Review). International Journal of Molecular Medicine. 607-613.
  • Vis forfatter(e) (2016). The possible role of gastrointestinal endocrine cells in the pathophysiology of irritable bowel syndrome. Expert Review of Gastroenterology & Hepatology. 139-148.
  • Vis forfatter(e) (2015). The relation between celiac disease, nonceliac gluten sensitivity and irritable bowel syndrome. Nutrition Journal.
  • Vis forfatter(e) (2015). Recent advances in the diagnosis of irritable bowel syndrome. Expert Review of Gastroenterology & Hepatology. 1161-1174.
  • Vis forfatter(e) (2014). Is irritable bowel syndrome an organic disorder? World Journal of Gastroenterology (WJG). 384-400.
  • Vis forfatter(e) (2014). Irritable bowel syndrome: recent developments in diagnosis, pathophysiology, and treatment. Expert Review of Gastroenterology & Hepatology. 435-443.
  • Vis forfatter(e) (2014). Interaction between ingested nutrients and gut endocrine cells in patients with irritable bowel syndrome (Review). International Journal of Molecular Medicine. 363-371.
  • Vis forfatter(e) (2014). Chronic constipation and treatment options (Review). Molecular Medicine Reports. 3-8.
  • Vis forfatter(e) (2013). The role of peptide YY in gastrointestinal diseases and disorders (Review). International Journal of Molecular Medicine. 275-282.
  • Vis forfatter(e) (2013). Clinical presentation, diagnosis, pathogenesis and treatment options for lymphocytic colitis (Review). International Journal of Molecular Medicine. 263-270.
  • Vis forfatter(e) (2012). Irritable bowel syndrome: treatment options. Clinical Practice. 591-600.
  • Vis forfatter(e) (2012). Ghrelin and the brain-gut axis as a pharmacological target for appetite control. Current pharmaceutical design. 768-775.

Se fullstendig oversikt over publikasjoner i CRIStin.